Companies › City Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular, Ophthalmology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CITY-RBP4 siRNA targeting RBP4 | RBP4 | Phase 1 | Stargardt Disease 1 | Feb 2028 |
| CITY-FXI siRNA targeting Factor XI | FXI | Phase 1 | Factor V Leiden | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07836452 | CITY-RBP4 | Phase 1 | Stargardt Disease 1 | Ophthalmology | Feb 2028 |
| NCT07430397 | CITY-FXI | Phase 1 | Factor V Leiden | Cardiovascular | Mar 2028 |
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.